US Earnings Financial Results SEC Filings — March 04, 2026

04-03-2026

04-03-2026

National Vision Holdings, Inc. reported FY2025 total net revenue of $1.99B, up 9.0% YoY from $1.82B, with comparable store sales growth accelerating to 5.9% from 1.9% driven by America's Best (+6.3%) and other owned segments. The company achieved net income from continuing operations of $29.6M, reversing a $27.2M loss, alongside Adjusted Operating Income of $102.5M (up 56% YoY) and Adjusted EBITDA of $193.0M (up 24%). However, new store openings slowed to 33 from 69, services and plans revenue grew slower at 6.3% versus 9.7% for products, and SG&A expenses rose 8.3% to $1.02B.

• ·Asset impairment declined to $2.0M from $39.9M YoY.
• ·Corporate and other revenue fell to $21.0M (1.0% of total) from $27.6M (1.5%).
• ·Adjusted Diluted EPS from continuing operations rose to $0.80 from $0.52.
• ·Stores in Fred Meyer segment reduced from 29 to 18.

04-03-2026

Kontoor Brands reported FY2025 net revenues of $3.15B, up 21% YoY from $2.61B, driven by the Helly Hansen acquisition ($476M), organic growth ($61M), and favorable FX ($8M); gross margin improved to 45.2% from 44.5%. However, operating income declined to $337M (10.7% margin) from $342M (13.1% margin) due to higher SG&A at 34.5% of revenues (vs 31.4%), with Wrangler up 6% in revenue but Lee down 5.1% with profit -23.1%. Helly Hansen contributed $460M revenue with 6.9% margin in its first year.

• ·Repurchased 369,955 shares under public program at weighted avg $67.58/share, $190M remaining authorization.
• ·SG&A expenses rose to 34.5% of revenues from 31.4%.
• ·Wrangler operating margin expanded to 23.0% from 20.3%.
• ·Other revenues surged 153% to $27.8M with margin turning positive at 13.7%.

04-03-2026

Black Rock Coffee Bar, Inc. (BRCB) grew total stores to 181 from 149 with 32 net new openings, boosting total revenue 24.5% YoY to $200.3M and same-store sales growth to 10.1% from 6.3%, while average unit volume rose to $1.286M from $1.186M. However, income from operations plummeted 85.1% to $0.9M from $6.0M, and net loss widened 130.1% to $16.5M from $7.2M, driven by SG&A expenses surging 63.6% to $41.3M amid rising store operating costs.

• ·Store operating costs and expenses rose 22.2% YoY to $141.6M, with other store operating expenses up 28.4%.
• ·Pre-opening costs increased 28.2% to $4.3M.
• ·Interest expense, net improved 15.9% to $9.4M due to lower expense.
• ·Filing date: March 04, 2026 for year ended December 31, 2025.

04-03-2026

Xponential Fitness reported system-wide sales growth of 13% YoY to $1.75B in 2025, with global studios increasing 7% to 3,097 and franchise revenue rising 10% to $193M, driving operating income of $20M versus a $54M loss in 2024. However, total revenue declined 2% YoY to $315M, same-store sales were flat at 0%, new studio openings dropped 20% to 341, and segments like equipment revenue (-35%) and merchandise (-12%) saw sharp declines, resulting in a net loss of $54M (improved from $99M but worse than 2023's $6M loss). AUV LTM edged up 2% to $695 but quarterly AUV declined 2% to $683.

• ·North America new studio openings net 2025: 160 (global net: 201)
• ·International franchise licenses sold new 2025: 112 (vs North America 67)
• ·Impairment of goodwill and other noncurrent assets 2025: $33M (down from $63M in 2024)
• ·Remaining studios obligated to open under MFAs EOY 2025: 767 (flat from 763 in 2024)

04-03-2026

Archimedes Tech SPAC Partners II Co. reported total assets of $241.3M as of December 31, 2025, primarily from $239.9M in its Trust Account following its February 12, 2025 IPO of 23M Units, with net income of $8.0M for the year driven by $8.7M in interest income. However, operating losses reached $0.8M from G&A expenses, shareholders' deficit expanded to $6.7M due to $24.6M accretion on redeemable shares, compared to a minor $54k deficit at year-end 2024 pre-IPO. The 2024 inception period showed a $79k net loss with negligible assets.

• ·IPO consummated on February 12, 2025, with full exercise of 3M over-allotment option; 750k sponsor shares no longer subject to forfeiture.
• ·Company inception date: June 7, 2024.
• ·Ordinary shares subject to redemption valued at $10.43 per share as of Dec 31, 2025.
• ·Promissory note to related party of $192k repaid by Dec 31, 2025.

04-03-2026

Cricut, Inc. reported FY2025 total revenue of $709M, down 1% YoY from $713M due to a 5% decline in Products revenue to $381M, despite 5% growth in Platform revenue to $327M. Gross profit rose 11% to $390M with margin expansion to 55% (Platform at 89%, Products up to 26%), driving operating income up 26% to $96M and net income up 22% to $77M. However, sales and marketing expenses increased 11% to $159M while R&D rose 10% to $67M.

• ·Stock-based compensation expense declined to $35M in FY2025 from $45M in FY2024.
• ·Provision for income taxes increased 20% YoY to $31M in FY2025.
• ·Total revenue down 7% from FY2023 $765M peak.
• ·G&A expenses down 6% YoY to $68M but flat at 10% of revenue.

04-03-2026

Gran Tierra Energy Inc. reported a significant net loss of $193.1M for the year ended December 31, 2025, compared to a $3.2M profit in 2024, driven by lower average sales prices ($42.53/boe vs. $60.92/boe, -30% YoY) and a $136.3M asset impairment, despite production NAR volumes surging 38% YoY to 38,443 BOEPD and total annual NAR boe rising 37% to 14.0M. Proved reserves declined 17% to 112 MMBOE, gross profit fell 64% to $66.4M, and Adjusted EBITDA dropped 23% to $283.7M, though net cash from operating activities increased 31% to $313.2M. Segment-wise, Colombia's operating netback plummeted while Ecuador and Canada saw gains.

• ·Senior Notes balance decreased 6% YoY to $740.5M with no credit facility draw as at Dec 31, 2025.
• ·Colombia operating netback declined to $240.0M in 2025 from $379.9M in 2024.
• ·Ecuador gross profit improved to $5.5M in 2025 from $2.3M in 2024.
• ·Q4 2025 net loss was $141.1M, including $136.3M asset impairment.

04-03-2026

Altisource Portfolio Solutions S.A. reported total revenue of $171M for the year ended December 31, 2025, up 7% YoY from $160M, driven by 16% growth in Origination service revenue to $35M and 5% increase in Servicer and Real Estate to $126M. However, gross profit declined 1% to $49M with margins contracting to 30% from 33%, income from operations fell 87% to $0.4M impacted by a $7.5M litigation settlement loss, and Marketplace revenue dropped 10% to $24M while Technology and SaaS Products declined 11% to $9M. The company achieved a net income attributable to Altisource of $1.6M, swinging from a $36M loss in 2024, supported by a 69% reduction in interest expense.

• ·REO Inventory - Customers other than Rithm increased 230% to 2.4 (in thousands) as of Feb 15, 2026 from 0.7.
• ·REO Inventory - Rithm remained flat at 1.0 (in thousands) as of Feb 15, 2026.
• ·Corporate and Others segment reported operating loss of $32.8M in 2025 vs $34.8M in 2024.
• ·SG&A expenses decreased 10% to $41M in 2025.
• ·Filing date: March 04, 2026 for year ended December 31, 2025.

04-03-2026

Cellectar Biosciences' total assets declined 41% YoY to $15.0M as of December 31, 2025 from $25.5M in 2024, driven by a 43% drop in cash and cash equivalents to $13.2M. While total liabilities improved 48% to $5.1M, highlighted by an 87% reduction in warrant liability to $0.23M, stockholders' equity fell 40% to $8.5M due to a $21.8M increase in accumulated deficit. Common shares outstanding more than doubled to 4.24M, with additional paid-in capital up 6% to $277M.

• ·Filing date: March 04, 2026
• ·Property, plant & equipment, net: $0.55M (2025) vs $0.76M (2024)
• ·Operating lease right-of-use asset: $0.36M (2025) vs $0.44M (2024)
• ·Accounts payable and accrued liabilities: $4.4M (2025) down 42% from $7.6M (2024)

04-03-2026

Advanced Flower Capital Inc. (AFCG) reported a net loss of $20.7M for the year ended December 31, 2025, compared to net income of $16.8M in 2024, primarily due to a 40% YoY decline in interest income to $31.3M, sharply higher provisions for credit losses at $22.6M (vs $4.2M), and unrealized losses on loans. Distributable earnings dropped 75% YoY to $8.7M amid a contracting loan portfolio with total outstanding principal at $317.4M (down from $301.8M). While expenses decreased slightly to $15.7M and there was a $0.4M gain on debt extinguishment, net interest income fell 46% YoY to $24.6M.

• ·Fair value of loans decreased to $26.1M as of 12/31/2025 from $30.5M as of 12/31/2024.
• ·Loan repayments of $60.6M and amortization payments of $18.2M contributed to portfolio contraction in 2025.
• ·New fundings totaled $41.7M in 2025.
• ·Weighted average remaining life of loans at carrying value shortened to 1.4 years as of 12/31/2025 from 1.9 years as of 12/31/2024.
• ·Largest loan exposure: Sub of Private Co. G at 22.0% of total AFC ($78.8M principal).

04-03-2026

TScan Therapeutics reported collaboration and license revenue of $10.3M for the year ended December 31, 2025, a 267% YoY increase from $2.8M. However, operating expenses rose 6% to $146.1M, resulting in a net loss of $129.8M, up 2% from $127.5M in 2024, while cash used in operating activities increased 22% to $135.3M and cash equivalents fell to $152.4M from $178.7M.

• ·Clinical studies expenses declined $2.4M to $16.8M in 2025 from $19.2M in 2024.
• ·Interest and other income, net decreased $3.2M to $8.8M in 2025.
• ·Marketable securities balance dropped to $0 from $111.4M at Dec 31, 2024.
• ·Stock-based compensation increased to $11.7M in 2025 from $9.5M in 2024.
• ·Accumulated deficit grew to $504.9M from $375.1M.

04-03-2026

04-03-2026

Alerus Financial Corp reported net interest income surging 61.1% YoY to $172.5M in 2025, fueled by a wider net interest margin of 3.53%, while retirement and benefit services AUA grew 10.3% to $44.9B and mortgage originations doubled to $484.8M. However, noninterest income plunged 54.9% YoY to $51.9M, noninterest expenses rose 11.4% to $201.2M, resulting in net income dipping 1.9% to $17.4M, diluted EPS falling to $0.68 from $0.83, and ROA declining to 0.33%. Loans increased modestly 1.4% to $4.05B, but deposits contracted 4.2% to $4.19B and nonperforming loans rose to 1.71%.

• ·Provision for loan losses decreased sharply to $556K from $18.1M YoY.
• ·Investment securities declined to $768.5M from $863.6M.
• ·Efficiency ratio worsened to 84.10% from 77.92%.
• ·Dividend payout ratio increased to 122.06% from 95.18%.
• ·Allowance for credit losses coverage of nonperforming loans fell to 89.65% from 95.30%.

04-03-2026

Unknown Company's total assets declined 19.8% YoY to $90.1B in 2025 from $112.4B in 2024, primarily due to a 32.3% drop in average advances balance to $49.4B and a 31.7% decrease in total interest income to $4.16B, resulting in net interest income falling 20.2% to $625.1M. While the net interest spread improved slightly to 0.44% from 0.42% and mortgage loans yield rose to 3.90% from 3.55%, noninterest income dropped sharply 61.3% to $18.6M and net income subject to AHP assessment decreased 28.9% to $465.6M.

• ·Statutory AHP assessment of $46.6M in 2025, down from $65.5M in 2024
• ·Total contributions to AHP $51.6M in 2025 including $5.0M supplemental voluntary
• ·Net interest margin stable at 0.70% in 2025 vs 0.71% in 2024

04-03-2026

SunOpta Inc. reported FY2025 revenues of $818M, up 13.0% YoY from $724M, driven by 13.5% volume/mix growth in beverages, broths, and fruit snacks, though partially offset by a -0.2% price impact and -0.3% from smoothie bowls exit. Gross profit rose 20.4% to $116M with margin expansion to 14.2% (up 0.9pt), and operating income surged 154.6% to $40M (margin 4.9%, up 2.7pt), leading to net earnings of $16M from a prior loss of $17M; however, COGS increased 11.8%, other non-operating expense rose 213%, and non-cash asset impairments totaled $3.2M.

• ·FY2025 revenue drivers: volume/mix +$97M (13.5%), price -$1M (-0.2%), smoothie bowls exit -$2M (-0.3%)
• ·FY2024 vs FY2023: revenues up 15.5% to $724M, but gross margin declined 0.4pt to 13.3%; SG&A flat at +1.0%
• ·Gross profit FY2025 improvements included $16M lower start-up costs and $14M higher volumes, offset by $10M labor/infrastructure investments and $2M depreciation
• ·Operating income FY2025 aided by $6M lower op ex (incl. consultancy savings) and $4M lower stock comp, but hurt by $3M impairments and $2M prior gain reversal
• ·Midlothian, Texas facility: $1M savings from lower wastewater charges

04-03-2026

Ocugen, Inc. reported total revenue of $4.4M for the year ended December 31, 2025, up 9% YoY from $4.1M, entirely from collaborative arrangements. However, R&D expenses surged 24% to $39.8M and total operating expenses rose 14% to $67.3M, driving operating losses to widen 15% YoY to $62.9M and net loss to expand 25% to $67.8M. Cash and restricted cash plummeted 68% to $18.9M, with net cash used in operations increasing 35% to $57.0M and stockholders' equity turning negative at $12.2M from $29.6M.

• ·Net cash provided by financing activities declined 73% YoY to $17.3M from $64.9M.
• ·Interest expense rose sharply to $5.2M from $0.7M due to higher debt.
• ·Diluted EPS worsened to $(0.23) from $(0.20).
• ·Common shares outstanding increased to 312.4M from 291.4M.
• ·Series B Convertible Preferred Stock fully reacquired in 2024.

04-03-2026

Sensus Healthcare reported revenues of $27.5M for FY 2025, a 34% YoY decline from $41.8M, resulting in a net loss of $7.7M compared to net income of $6.6M in FY 2024, driven by higher R&D ($7.8M, +85%) and selling expenses ($6.5M, +31%). While cash and equivalents remained stable at $22.1M and operating cash flow improved to positive $0.5M from negative $0.8M, total assets fell 15% to $53.0M amid a sharp 69% drop in accounts receivable to $6.0M.

• ·Stock repurchases of 50,360 shares for $0.3M in FY 2025.
• ·Deferred tax assets increased to $4.1M from $2.2M.
• ·Total stockholders’ equity declined to $48.1M from $55.8M.
• ·Company notes potential need for additional funding in future.

04-03-2026

Westlake Chemical Partners LP's 2025 annual results showed total net sales of $1.17B, up 2.7% YoY from $1.14B, with net sales to Westlake rising 8.7% to $1.03B while third-party co-products sales declined 28% to $133M; the increase was driven by 10.4% higher average sales prices offsetting an 8.2% volume drop. However, gross profit fell 17% to $348M amid 50.7% higher natural gas fuel costs and 32.8% higher ethane feedstock costs, resulting in income from operations down 18% to $320M, net income to LP down 22% to $48.7M (or $1.38 per unit from $1.77), and MLP distributable cash flow down 20% to $53.4M. EBITDA decreased 11% to $450M, and net cash from operations dropped sharply 42% to $280M.

• ·Property, plant and equipment, net declined to $886M from $904M.
• ·Long-term debt payable to Westlake stable at $400M.
• ·Distributions to unitholders remained flat at approximately $66M.
• ·Cash and cash equivalents ended at $44M, down from $58M.

04-03-2026

For the three months ended January 31, 2026, Highwater Ethanol reported revenues of $34.4M, up 3.6% YoY from $33.2M, driven by strong 27% growth in corn oil sales to $3.3M, while modified distillers grains sales declined 8% to $1.5M and dried distillers grains remained flat at $3.8M. Gross profit surged to $3.5M from $1.0M YoY due to lower COGS, yielding operating income of $2.1M versus a prior loss, but net income fell to $5.6M from $8.3k primarily due to timing of $3.3M tax credits. Cash and total assets declined QoQ to $19.8M and $87.4M, respectively, amid $6.7M member distributions.

• ·Operating expenses increased to $1.4M from $1.3M YoY.
• ·Net cash provided by operating activities was $4.3M versus $(9.7M) YoY.
• ·Capital expenditures of $1.4M in the quarter.
• ·Distributions declared per unit: $1,400 (2026) vs $1,700 (2025).
• ·Net income per unit: $1,180.54 (2026) vs $1.75 (2025).

04-03-2026

First Financial Corp (THFF) reported 2025 net income of $79.2M, up 67.5% YoY from $47.3M, fueled by 25.6% growth in net interest income to $219.9M and a reduced provision for credit losses to $8.2M from $16.2M. However, deposits declined 3.6% YoY to $4.55B amid rising borrowings to $480.7M, non-interest expenses increased 7.3% to $154.9M, and securities holdings fell to $1.15B. Total assets grew 3.6% to $5.76B, loans expanded 5.7% to $4.06B, ROE rose to 13.3% from 8.8%, and cash dividends increased to $2.04 per share.

• ·Securities declined to $1.15B from $1.20B YoY.
• ·Non-interest income slightly down to $42.0M from $42.8M.
• ·Cash dividends declared per share increased quarterly, reaching $0.56 in Q4 2025 from $0.51 in Q4 2024.
• ·Stock price high reached $61.25 in Q4 2025, up from $50.61 in Q4 2024.

04-03-2026

Daktronics reported Q3 FY26 net sales of $181.9M, up 21.7% YoY from $149.5M, and 9M sales of $630.1M, up 8.0% YoY from $583.9M, driving operating income of $1.9M in Q3 (vs $3.6M loss) and $46.8M in 9M (up 34.1% YoY), with net income of $3.0M and $37.0M respectively (vs losses). However, cash from operations fell 27.4% YoY to $54.3M for 9M due to unfavorable working capital changes, while inventories dipped slightly to $103.6M from $105.8M YoY and the company spent $22.8M on share repurchases. Total assets grew to $546.4M from $502.9M at FY25 end.

• ·Treasury stock at cost increased to $(62.5M) from $(39.8M) at FY25 end due to repurchases.
• ·Accounts receivable, net rose to $114.3M from $92.8M at FY25 end.
• ·Stockholders' equity grew to $293.7M from $271.9M at FY25 end.

04-03-2026

UNL's net asset value per share declined 9.6% YoY to $7.34 at December 31, 2025, from $8.12, amid a 20.9% drop in average daily total net assets to $14.3M and ongoing net loss of $971k (narrowed 20% from $1.2M in 2024). While Partners’ Capital remained stable at $18.7M with slight 0.2% growth, total assets fell 1.2% to $18.8M and dividend/interest income decreased 35% to $586k with yield down to 4.09%. Commodity futures trading showed mixed results with $1.86M realized gains but $3.19M unrealized losses.

• ·Unrealized loss on open commodity futures contracts: $(2.07M) at Dec 31 2025 vs gain $1.12M at Dec 31 2024.
• ·Realized gain on closed commodity futures: $1.86M in 2025 vs loss $(7.41M) in 2024.
• ·Net cash from operating activities: $1.95M in 2025 vs $(6.33M) in 2024.
• ·Tax risk: Potential reallocation of income/gain items by IRS could make UNL liable for federal income tax.

04-03-2026

Oil States International, Inc. (OIS) reported FY2025 revenues of $669M, down 3.4% YoY from $693M, driven by an 8.4% increase in Products to $436M but a 19.8% decline in Services to $233M; Offshore Manufactured Products grew 8.3% to $431M with operating income up 6% to $69M, while Completion and Production Services fell 30% but swung to $4M profit from a $23M loss. The company posted a net loss of $109M versus $11M in 2024, primarily due to $100M in impairments (up from $25M) leading to an operating loss of $98M, though operating cash flow rose 129% to $105M and long-term debt dropped to $1.7M from $125M.

• ·Total assets declined to $883M from $1,005M YoY.
• ·Stockholders’ equity fell to $573M from $681M, impacted by $109M net loss and $17M stock repurchases.
• ·Inventory impairment of $21M in FY2025.
• ·Treasury stock purchases totaled $17M in FY2025.

04-03-2026

Bankwell Financial Group, Inc. reported strong recovery in 2025 with net income surging 260% YoY to $35.2M from $9.8M in 2024, fueled by net interest income growth of 19% to $98.9M, total revenue up 25% to $108.3M, and provision for credit losses dropping sharply to $1.0M from $22.6M. Asset quality improved markedly with nonperforming assets to total assets at 0.49% versus 1.88% in 2024, and return on average assets rose to 1.09% from 0.31%. However, noninterest expenses increased 15% YoY to $58.8M due to higher salaries and professional services, while efficiency ratio improved modestly to 54.1% from 57.9%.

• ·Provision for credit losses declined to $1.0M in 2025 from $22.6M in 2024.
• ·Net (recoveries) charge-offs to average loans at -0.01% in 2025 vs 0.81% in 2024.
• ·Tier 1 capital to risk-weighted assets for Bankwell Bank at 11.87% in 2025 (up from 11.64%).
• ·Gains and fees from sales of loans jumped to $5.1M in 2025 from $0.5M in 2024.

04-03-2026

Verastem, Inc. reported total revenue of $30.9M for the year ended December 31, 2025, driven by $30.9M in new product revenue, up significantly from $10M in 2024 from the COPIKTRA license sale to Secura. However, operating expenses increased 61% YoY to $201M, with R&D up 41% to $114.6M and SG&A surging 86% to $81.1M, leading to a widened net loss of $209.5M from $130.5M in 2024. The company highlighted risks including regulatory approval delays, commercialization challenges, and potential impacts on milestone payments and royalties from Secura.

• ·Optional third tranche purchase of up to $50M Notes available prior to December 31, 2026, contingent on trailing six-month net sales of avutometinib and defactinib reaching at least $55M.
• ·Cost of sales - product: $4.6M in 2025; Cost of sales - intangible amortization: $0.7M in 2025.
• ·Loss from operations worsened to $(170.1M) in 2025 from $(115.0M) in 2024.

04-03-2026

Brown-Forman reported nine-month net income of $661M, down 9% YoY from $723M, with three-month net income also slightly declining 1% to $267M from $270M; diluted EPS for nine months fell 8% to $1.41 from $1.53. However, operating cash flow surged 59% YoY to $709M from $446M, comprehensive income rose to $793M for nine months, and total assets grew 3% sequentially to $8.3B as of January 31, 2026. The company repurchased $400M in treasury stock, contributing to lower cash of $383M, while restructuring charges decreased to $19M for nine months.

• ·Restructuring charges for nine months ended Jan 31, 2026 totaled $19M, down from $33M prior year.
• ·Proceeds from sale of equity method investment $350M in prior nine months; none in current.
• ·Total inventories increased to $2,560M as of Jan 31, 2026 from $2,511M.
• ·Goodwill increased to $1,536M from $1,505M due to foreign currency translation.
• ·Other intangible assets net $1,088M as of Jan 31, 2026, up from $981M.

04-03-2026

Grocery Outlet Holding Corp. reported FY ended January 3, 2026 net sales of $4.69B, up 7.3% YoY from $4.37B, with gross profit rising 7.4% to $1.42B and adjusted EBITDA improving to $254M from $237M. However, the company recorded an operating loss of $222M versus prior-year income of $78M, net loss of $225M versus $39M profit, driven by $149M goodwill impairment, $114M long-lived assets impairment, restructuring charges up 189% to $46M, and SG&A expenses up 8.5%; comparable store sales increased only 0.5% (flat, down from 2.7%). Store count reached 570, up from 533, but new stores opened fell to 42 from 67.

• ·GAAP diluted EPS: $(2.30) vs $0.40 prior year; Adjusted diluted EPS flat at $0.76 vs $0.77.
• ·EBITDA: $(91M) vs $187M prior year.
• ·Adjusted net income: $75M vs $76M prior year (flat).

04-03-2026

Keros Therapeutics reported total revenue of $244M for the year ended December 31, 2025, surging 6,772% YoY from $3.6M, primarily from $205M in license revenue and $39M in service revenue, leading to net income of $87M versus a $187M loss in 2024 and positive operating cash flow of $108M versus a $161M outflow. R&D expenses declined 25% to $130M while G&A rose 15% to $47M. However, cash and equivalents fell 49% to $287M from $560M, total assets dropped 45% to $338M from $616M, and stockholders' equity decreased 47% to $303M, driven by a $385M repurchase of 21.1M treasury shares that halved outstanding shares to 19.5M.

• ·EPS basic $2.34 in 2025 vs ($5.00) in 2024.
• ·Net cash used in financing activities ($378M) in 2025 vs provided by $392M in 2024 due to no issuances and $375M repurchase.
• ·Stock-based compensation expense $29M in 2025 vs $35M in 2024.
• ·Income tax provision $4.9M in 2025 vs $0.3M in 2024.
• ·Cash paid for taxes $7.1M in 2025.

04-03-2026

SCYNEXIS INC reported total revenue of $20.6M for the year ended December 31, 2025, surging 449.9% YoY from $3.7M, driven by $1.4M in new product revenue and license agreement revenue up 411.4% to $19.2M. Operating expenses declined 10.2% to $36.7M, narrowing the net loss 59.6% to $8.6M from $21.3M; however, total assets contracted to $59.0M from $90.6M, short-term investments fell to $18.8M from $43.2M, and stockholders' equity decreased to $49.4M from $55.1M.

• ·Net cash used in operating activities improved to $(5.3M) in 2025 from $(24.0M) in 2024.
• ·Net cash provided by investing activities was $24.3M in 2025 vs $6.2M in 2024.
• ·Weighted average common shares outstanding basic and diluted: 49,933,381 in 2025 vs 48,513,073 in 2024.
• ·Stock-based compensation expense: $2.9M in 2025 vs $3.3M in 2024.

04-03-2026

Niagen Bioscience, Inc. reported total net sales of $129.4M for the year ended December 31, 2025, up 30% YoY from $99.6M, driven by strong growth in Consumer Products (+27%) and Ingredients (+45%). However, the Analytical Reference Standards and Services segment showed flat growth of only 2% YoY. Net income increased to $17.4M from $8.6M, supported by gross profit growth of 35% to $83.2M and a gain on settlement of royalty obligation, though general and administrative expenses rose significantly to $27.1M from $18.4M.

• ·Basic EPS increased to $0.22 from $0.11 YoY.
• ·Diluted EPS increased to $0.20 from $0.11 YoY.
• ·Sales and marketing expenses rose 20% to $35.5M from $29.5M.
• ·Research and development expenses increased slightly to $6.3M from $6.0M.
• ·Interest income, net rose to $2.1M from $1.1M.
• ·IRS ERTC disallowance of $0.2M in 2025.
• ·Provision for income taxes $0.8M in 2025 vs $0.3M in 2024.

04-03-2026

Sight Sciences, Inc. (SGHT) reported FY2025 revenue of $77.4M, down 3.1% YoY from $79.9M, with Interventional Glaucoma nearly flat at -0.2% ($75.7M) but Interventional Dry Eye plunging 58.7% to $1.6M. While gross margins improved slightly to 86.2% and operating expenses fell 12.7% to $103.8M, leading to a narrowed net loss of $38.4M (improved 25.4% YoY), cash and equivalents dropped to $92.0M from $120.4M due to higher operating cash burn of $29.7M.

• ·Total assets declined to $115.3M from $142.8M as of Dec 31, 2025 vs 2024.
• ·Stockholders’ equity decreased to $63.9M from $87.5M.
• ·Long-term debt increased slightly to $40.3M from $39.4M.
• ·Stock-based compensation expense fell to $13.1M from $17.1M.

04-03-2026

COMPX International Inc reported net sales of $158.3M for 2025, up 8% from $145.9M in 2024 but still below 2023's $161.3M after a 10% YoY decline the prior year. Operating income rebounded 33% YoY to $22.6M (14.3% of sales) from $17.0M, with gross margin improving 16% to $48.2M (30.4%), however operating costs rose 5% to $25.6M and remained elevated at 16.2% of sales compared to 2023 levels.

• ·Goodwill of $23.7M at Dec 31, 2025, all related to Security Products reporting unit; tested annually in Q3 or upon triggering events.
• ·Net book value of property and equipment $23.7M at Dec 31, 2025; assessed for impairment based on future cash flows when indicators exist.
• ·Cost of sales $110.1M in 2025 (69.6% of sales), up 5% from $104.6M in 2024.

04-03-2026

Orion Group Holdings Inc reported contract revenues of $852.3M for FY2025, up 7% YoY from $796.4M, driven by growth in state/local governments (+57% and +29%) and private companies (+13%), though federal government revenues declined 30% YoY. Gross profit rose 16% to $105.6M and operating income increased 27% to $14.6M, with Marine segment revenues up 5% and operating income surging to $29.9M from $2.3M; however, Concrete segment posted an operating loss of $15.3M versus $9.2M profit prior year despite 12% revenue growth, and cash equivalents dropped sharply to $1.6M from $28.3M amid high capital expenditures of $38.9M.

• ·Net income turned positive at $2.5M in FY2025 from $1.6M loss in FY2024 and $17.9M loss in FY2023.
• ·Interest expense declined 34% YoY to $8.9M from $13.4M.
• ·Long-term debt reduced to $6.1M from $22.8M at year-end.
• ·Basic EPS improved to $0.06 from $(0.05).

04-03-2026

NN Inc reported net sales of $422.2M for FY 2025, down 9.1% YoY from $464.3M, while net loss narrowed to $34.0M from $38.3M, an 11.2% improvement driven by lower cost of sales and depreciation. Operating loss improved to $18.9M from $27.5M; however, Mobile Solutions segment sales declined 14.1% to $244.0M with persistent losses, while the other segment (likely Life Sciences) saw nearly flat sales (-1.1% to $178.6M) but operating income fell 21.3% to $10.3M. Total assets decreased to $440.8M from $456.9M, with long-term debt at $153.8M.

• ·Depreciation and amortization declined 20.7% YoY to $35.9M from $45.3M.
• ·Share of net income from joint venture flat at 2.1% of sales but absolute value down 7.3% to $8.9M.
• ·Basic and diluted net loss per share improved to $(1.07) from $(1.11).
• ·Cash and cash equivalents down to $11.4M from $18.1M; inventories up 6.6% to $66.0M.

04-03-2026

PepGen Inc. reported a slightly narrower net loss of $89.7M for the year ended December 31, 2025, compared to $90.0M in 2024, with operating expenses declining 4.2% YoY to $93.6M driven by a 7.1% drop in R&D expenses, though G&A rose 6.2%. Cash and equivalents grew 22.5% to $60.5M, bolstered by $108M net proceeds from a public offering, resulting in a net cash increase of $11.1M versus a $31.4M decrease prior year; however, interest income fell 43.7% to $4.0M and shares outstanding more than doubled to 68.9M, diluting EPS to $(2.12) from $(2.85). Total assets expanded 15.3% to $173.9M, but accumulated deficit widened to $361.1M.

• ·Stock-based compensation expense declined to $10.6M from $11.5M YoY.
• ·Net cash used in investing activities improved to $(15.2M) from $(37.7M), with lower purchases of marketable securities.
• ·Accumulated deficit increased to $361.1M from $271.5M.
• ·Employment agreements executed with executives on May 20, 2025 (Kasra Kasrarian, PhD), August 19, 2024 (Paul D. Streck), and December 8, 2025 (Joseph Vittiglio).

04-03-2026

Rigetti Computing's 2025 revenue declined 34% YoY to $7.1M from $10.8M, with gross profit dropping 64% to $2.1M despite a 1% reduction in cost of revenue. Operating expenses increased 17% to $86.7M, driven by 23% higher R&D, resulting in a widened operating loss of $84.7M (up 24%) and net loss of $216.2M (up 8% YoY). However, the balance sheet strengthened significantly, with total assets more than doubling to $666.6M from $284.8M, bolstered by $545.0M in short- and long-term investments and stockholders' equity rising to $546.2M.

• ·Cash and cash equivalents decreased to $44.9M from $67.7M as of Dec 31, 2025 vs 2024.
• ·Derivative warrant liabilities increased to $102.6M from $93.1M.
• ·Common stock shares outstanding rose to 331.3M from 283.5M.
• ·Available-for-sale investments (short-term + long-term) surged to $544.9M from $149.5M.

04-03-2026

For the quarter ended January 30, 2026, Cracker Barrel reported revenue of $875M, down 7.9% YoY from $949M, with net income falling sharply to $1.3M from $22.2M amid higher impairments and weak operating income of $0.5M versus $29.1M prior year. Six-month revenue declined 6.8% YoY to $1.67B, swinging to a $23.3M net loss from $27.1M profit, though G&A expenses dropped 22% YoY to $48M in the quarter. Total assets decreased to $2.10B from $2.16B at fiscal year-end, with cash equivalents falling to $8.6M from $39.6M.

• ·Cash flows from operating activities for six months: -$2.2M vs $93.7M prior year.
• ·Long-term debt increased to $382M from $335M sequentially.
• ·Shareholders’ equity declined to $426M from $462M sequentially.
• ·Property and equipment capex six months: $62M vs $77M prior year.
• ·Dividends declared six months: $0.25 per share, total ~$12M.

04-03-2026

Atlas Lithium Corp reported total assets of $87.7M as of Dec 31, 2025, up 51.6% YoY from $57.9M, driven by cash and equivalents surging 131% to $35.9M and property/equipment rising 23.4% to $48.0M. However, accumulated deficit widened 18.8% to $171.6M from $144.4M, reflecting higher G&A expenses up $6.7M, while total liabilities remained nearly flat at $35.2M and stockholders' equity grew 138% to $52.5M amid share count increasing 68% to 27.0M shares outstanding.

• ·Current liabilities increased to $14.8M from $5.7M YoY.
• ·Trade receivables declined to $28,539 from $47,682.
• ·Capitalized exploration costs decreased $1.6M to $2.9M from $4.5M.
• ·G&A expenses increased $6.7M due to personnel and infrastructure growth.
• ·Exploration costs decreased $3.0M due to capitalization.
• ·Intangible assets acquisition decreased $0.4M.

04-03-2026

ASPAC III Acquisition Corp. reported net income of $1.34M for the year ended December 31, 2025, a turnaround from a $0.23M loss in 2024, driven by $2.17M in interest income (+502% YoY), though operating losses widened to $0.83M (+41% YoY) due to higher G&A (+40%) and legal expenses (+41%). However, the balance sheet deteriorated sharply with total assets falling 94% YoY to $3.94M from $62.08M, primarily due to massive redemptions reducing trust account investments by 95% to $2.98M and cash declining 45% to $0.87M, while shareholders' equity dropped 89% to $0.42M.

• ·Promissory note - related party: $0 as of Dec 31, 2025 (down from $276,221 as of Dec 31, 2024)
• ·Basic and diluted net income per redeemable Class A share: $0.47 (2025) vs $0.50 (2024)
• ·Basic and diluted net loss per non-redeemable Class A and B share: ($0.49) (2025) vs ($0.38) (2024)
• ·Up to 206,250 Class B shares subject to forfeiture related to underwriter over-allotment option

04-03-2026

Janus International Group, Inc. (JBI) reported total revenue of $884.2M for the year ended January 3, 2026, down 8.3% YoY from $963.8M, primarily due to an 11.9% decline in product revenues to $686.9M, though service revenues grew 7.0% to $197.3M partly from $7.3M in acquisition revenue offsetting a 9.0% organic decline. Adjusted EBITDA fell 19.3% to $168.2M (19.0% margin vs. 21.6%), with self-storage segments down 9.7% overall (new construction -12.6%, R3 -4.9%), while the acquired entity showed strong growth of 41.2% to $103.9M. Net income decreased 23.6% to $53.8M amid higher operating leverage challenges.

• ·Gross profit declined 13.8% YoY to $343.0M.
• ·Operating expenses decreased 7.8% to $231.5M, driven by lower impairment charges (-94.2%).
• ·Interest expense, net improved 25.8% to $36.8M.
• ·Organic product cost of revenues declined 8.5%.
• ·Acquired entity Adjusted EBITDA surged 427.3% to $11.6M.

04-03-2026

Cardlytics, Inc. reported 2025 revenue of $233.3M, down 16% YoY from $278.3M in 2024 and continuing a decline from $309.2M in 2023, with billings falling 13% to $385.0M amid weakness in both Cardlytics platform (-13% billings) and Bridg platform (-8% billings). However, gross profit declined less sharply to $104.6M (-13% YoY), net loss narrowed significantly to $103.5M from $189.3M, Adjusted EBITDA improved to $10.1M (up 299% YoY), and operating cash flow turned positive at $9.3M versus prior cash burn. Free cash flow remained negative at $6.5M but improved from $28.1M burn.

• ·Sales and marketing expense declined to $39.5M in 2025 from $52.6M in 2024 (-25% YoY)
• ·Research and development expense fell to $39.8M from $49.6M (-20% YoY)
• ·Impairment charges of $58.8M in 2025, down from $131.6M in 2024
• ·Adjusted Net Loss per share improved to $(0.33) from $(0.39) diluted
• ·Restructuring and reduction of force costs: $3.8M in 2025
• ·Gain on divestiture: $4.8M in 2025

04-03-2026

Miller Industries Inc. (MLR) reported net sales of $790.3M for the year ended December 31, 2025, down 37.2% YoY from $1.26B in 2024, with gross profit declining 29.5% to $120.4M and net income falling 63.8% to $23.0M from $63.5M. While selling, general, and administrative expenses rose modestly 3.1% to $89.0M, operating cash flow improved dramatically 485.2% to $98.7M, driving a net increase in cash to $44.7M, and long-term obligations decreased to $31.1M from $65.0M. Total assets stood at $589.7M with shareholders' equity up to $420.6M despite the revenue drop.

• ·Diluted EPS $1.98 in 2025 vs $5.47 in 2024 (down 63.8%)
• ·Cash dividends declared per share $0.80 in 2025 (up from $0.76 in 2024)
• ·Inventories net flat at $184.2M vs $186.2M YoY
• ·Allowance for credit losses $1.876M (0.9% of receivables) vs $1.850M (0.6%) YoY
• ·Weighted-average diluted shares 11,615 thousand in 2025 (up slightly from 11,602 thousand)

04-03-2026

MicroVision, Inc. reported a net loss of $95.0 million for the year ended December 31, 2025, increasing its accumulated deficit to $957.3 million. Revenue declined sharply 74.3% YoY to $1.2 million from $4.7 million in 2024, while cost of revenue surged 146.3% to $18.5 million; however, sales, marketing, general, and administrative expenses decreased 30.7% to $20.3 million. Impairment losses on intangible assets rose 140.5% to $10.1 million, and interest expense increased 315.8% to $18.5 million.

04-03-2026

Aquestive Therapeutics, Inc. reported total revenues of $44.5M for the year ended December 31, 2025, down 23% YoY from $57.6M, driven by a sharp 77% decline in license and royalty revenue to $3.5M and 34% drop in co-development fees, though manufacture and supply revenue edged up 1% to $40.2M. Net loss widened to $83.8M from $44.1M, with operating loss at $71.1M versus $30.8M amid 59% higher SG&A expenses to $79.8M. Cash and equivalents increased to $121.2M from $71.5M, supported by $102.6M in financing activities including public equity offerings.

• ·Clinical trials costs declined 61% YoY to $3.5M.
• ·Stockholders’ deficit improved to -$33.7M from -$60.2M.
• ·Public equity offerings raised approximately $107M gross in 2025.
• ·Share-based compensation expense rose to $7.5M from $7.1M.

04-03-2026

Westwood Holdings Group, Inc. reported 2025 total revenues of $97.8M, up 3% YoY from $94.7M, with net income attributable to the company surging 219% to $7.1M from $2.2M amid lower expenses and higher net operating income. However, total AUM dipped 0.4% to $16.5B from $16.6B, reflecting worsened net client outflows of $1.0B versus $0.8B in 2024, with declines in Wealth Management (-1.7%) and Mutual Funds & ETFs (-0.6%) AUM partially offset by flat Institutional AUM. Economic Earnings doubled 105% to $14.3M, while Advisory net income rose 13% to $19.9M.

• ·Asset-based advisory fees grew 7% YoY to $74.7M in 2025, while performance-based fees declined 37% to $0.9M.
• ·Total expenses decreased 1% YoY to $92.8M in 2025.
• ·AUA end 2025 at $942M, down from $960M end 2024.
• ·2024 quarterly revenues: Q1 $17.2M, Q2 $15.6M, Q3 $15.4M, Q4 $20.5M.

04-03-2026

TriplePoint Venture Growth BDC Corp. (TPVG) reported portfolio fair value growth of 16% YoY to $784M at December 31, 2025, supported by $283M in new debt investments, increasing total debt investments 15% to $645M primarily in growth capital loans (95.6%). However, net investment income declined 23% YoY to $42M with weighted average yield dropping to 13.7% from 15.7%, NAV per share slipped slightly to $8.73 in Q4 2025 amid a downward trend from $9.02 in Q1 2024, and shares traded at widening discounts to NAV reaching -40% at 2025 lows. Portfolio companies expanded to 55 from 44, but included higher-risk Orange (3.9%) and Red (0.6%) credits.

• ·Principal prepayments and early repayments totaled $135M in 2025 vs $179M in 2024.
• ·Credit breakdown at Dec 31, 2025: White 75.1% ($485M, 43 cos), Yellow 13.4% ($86M, 4 cos), Orange 3.9% ($25M, 4 cos), Red 0.6% ($4M, 1 co).
• ·Interest rate sensitivity: Net investment income increases $7M if rates up 300bps, resilient with $1.7M gain even if down 300bps.
• ·Distributions: Q4 2025 $0.25/share, down from $0.30/share in Q4 2024; Q1 2026 partial $0.23/share.

04-03-2026

Third Coast Bancshares, Inc. reported net income of $66.3M for the year ended December 31, 2025, up 39.1% YoY from $47.7M in 2024, fueled by net interest income growth of 21.4% to $195.2M and noninterest income increase of 28.5% to $13.7M, with net interest margin expanding to 4.06%. However, provision for credit losses rose 33.1% to $7.6M, signaling potential credit pressures, while noninterest expenses increased 13.6% to $118.5M. Compared to 2023, 2024 net income grew 42.7% to $47.7M.

• ·Average yield on gross loans declined slightly to 7.68% in 2025 from 7.80% in 2024.
• ·(Loss) gain on sale of investment securities available-for-sale worsened to ($0.6M) in 2025 from ($0.0M).
• ·Service charges and fees surged 55.1% YoY to $10.8M in 2025.
• ·Salaries and employee benefits, the largest noninterest expense, rose 18.5% to $77.2M.

04-03-2026

Global Water Resources, Inc. reported FY2025 revenue growth of 5.8% YoY to $55.8M from $52.7M, driven by water service revenue up 9.8% and total active connections increasing 6.3% to 68,577. However, operating expenses rose 12.2% to $48.6M, resulting in operating income declining 23.6% to $7.2M and net income dropping sharply 48.9% to $3.0M with EPS at $0.11 (down from $0.24). Total assets expanded to $483M from $405M, supported by utility plant growth.

• ·Approved ROE ranges 9.20%-9.60% across utilities; recent GW-Farmers rate case approved $1.1 incremental annual revenue effective May 1, 2025.
• ·Pending rate cases for GW-Santa Cruz and GW-Palo Verde filed March 5, 2025.
• ·Shareholders' equity increased to $86.6M from $47.6M; long-term debt $129.8M.
• ·Dividends declared per common share remained flat at $0.30.

04-03-2026

Mayville Engineering Company, Inc. (MEC) reported net sales of $546.5M for the year ended December 31, 2025, down 6% YoY from $581.6M in 2024, amid macroeconomic pressures including inflation and material costs. Net income swung to a $8.1M loss from $26.0M profit in 2024, with EBITDA dropping 54% to $37.4M (6.9% margin) and Adjusted EBITDA declining 27% to $47.1M (8.6% margin); however, free cash flow remained positive at $26.9M despite a 65% YoY drop from $77.7M.

• ·Capital expenditures: $11.6M in 2025 vs $12.1M in 2024.
• ·Interest expense: $10.2M in 2025, slightly down from $11.0M in 2024.
• ·Acquisition related costs: $3.4M in 2025.
• ·Natural disaster costs: $0.3M in 2025.

04-03-2026

Nine Energy Service, Inc. reported revenues of $561.9M for the year ended December 31, 2025, up 1% YoY from $554.1M, driven by a 2% increase in service revenues to $431.2M, while product revenues declined slightly to $130.7M. However, the company posted a larger net loss of $51.3M (25% worse YoY) versus $41.1M in 2024, with operating income dropping 74% to $2.3M and Adjusted EBITDA falling to $49.4M from $53.2M. Cash and cash equivalents decreased to $18.4M from $27.9M, total debt rose to $369.6M, and stockholders' deficit widened to $(115.0M) from $(66.1M).

• ·Gross profit slightly declined to $60.6M from $61.1M YoY.
• ·Net cash used in operating activities was $7.3M in 2025 versus $13.2M provided in 2024.
• ·Total assets decreased to $339.5M from $360.1M.
• ·ROIC worsened to -20.8% from -14.9%, while Adjusted ROIC improved to 4.4% from 3.7%.
• ·Loss per share (basic and diluted) was $(1.25) versus $(1.11) YoY.

04-03-2026

European Wax Center, Inc. reported total revenue of $206.6M for FY2026 ended January 3, 2026, down 4.7% YoY from $216.9M, driven by declines in product sales (-7.3%) and flat same-store sales growth of 0.2%, amid net center closures of 20 (total centers 1,047 vs 1,067). Net income fell 19.2% to $11.9M, with income attributable to EWCZ down 17.0% to $8.7M, though Adjusted EBITDA remained relatively stable at $73.3M (down 2.9%) and operating income margin contracted to 20.7% from 22.0%. Cash and equivalents strengthened to $76.1M from $49.7M, boosting total assets to $725.3M.

• ·Cash flow from operating activities: $53.0M FY2026 vs $56.5M FY2025 (down 6.2%)
• ·Long-term debt stable at ~$375M
• ·Treasury stock increased to 9.8M shares from 8.4M shares
• ·Weighted average basic shares Class A: 43.4M FY2026 vs 46.8M FY2025

04-03-2026

Octave Specialty Group Inc reported total revenues of $251.2M for FY 2025, up 6.5% YoY from $235.8M, driven by strong Insurance Distribution segment growth with premiums placed nearly doubling to $951.8M (+93%) and commissions rising 56% to $143.4M. However, the company posted a widened net loss from continuing operations of $(95.8M) vs $(58.9M) in 2024, with Specialty Property & Casualty Insurance seeing gross premiums written decline 5.8% to $360.4M, net premiums written drop 17% to $73.9M, and combined ratio worsen to 105.2%. Operating cash flow turned negative at $(52.3M) from positive $0.8M.

• ·Adjusted EBITDA attributable to shareholders FY2025: $(7.5M) vs $2.2M FY2024
• ·Specialty P&C retention ratio declined to 20.5% from 23.2% YoY
• ·Insurance Distribution pretax loss $(20.5M) vs $(7.8M) YoY, despite revenue growth
• ·Corporate & Other pretax loss $(83.9M) vs $(64.3M) YoY
• ·Net cash flow FY2025: $21.4M vs $28.6M FY2024

04-03-2026

Red Violet, Inc. reported FY2025 revenue of $90.3M, up 20% YoY from $75.2M, with net income surging 88% to $13.2M, Adjusted EBITDA increasing 31% to $31.0M, and Adjusted EBITDA margin expanding to 34% from 31%. Q4 2025 revenue grew 20% YoY to $23.4M and net income rose 226% to $2.8M, but operating cash flow remained flat YoY at $6.7M while free cash flow declined 17% to $3.7M, and income from operations fell QoQ from $4.6M in Q3 to $1.6M.

• ·Total assets grew to $112.0M from $98.5M as of Dec 31, 2025.
• ·Cash and equivalents increased to $43.6M from $36.5M.
• ·Gross margin stable at 72% for FY2025 and Q4.
• ·Adjusted gross margin improved to 84% FY2025 from 81%.
• ·Accounts receivable net $10.7M (Dec 2025) vs $8.1M (Dec 2024).
• ·Intangible assets net $39.3M (Dec 2025) vs $36.0M (Dec 2024).

04-03-2026

Unity Bancorp, Inc. reported strong FY2025 results with net income per diluted share up 39.7% to $5.67 from $4.06 in FY2024, driven by net interest income increasing 18.7% to $117.0 million and noninterest income surging 74.5% to $14.8 million. However, noninterest expenses rose $3.7 million to $52.4 million due to higher compensation, processing, and occupancy costs. Net income before provision for income taxes grew 38.8% to $75.5 million, with GAAP net income at $58.0 million versus $41.5 million prior year.

• ·Return on average assets improved to 2.17% from 1.68%.
• ·Return on average equity rose to 18.07% from 14.99%.
• ·Dividend payout ratio decreased to 10.23% from 12.81%.
• ·Adjusted net income (non-GAAP) increased to $51.8M from $41.5M after adjustments for securities gains and credit loss releases.

04-03-2026

NACCO Industries reported FY2025 total revenue of $277.2M, up 16.6% YoY from $237.7M, with Utility Coal Mining surging 28.5% to $88.2M and Contract Mining growing 17.1% to $140.0M, while Minerals and Royalties increased 8.9% to $37.6M. However, operating profit fell 38.4% to $22.0M from $35.7M, primarily due to higher unallocated items losses and a $7.8M pension settlement charge, resulting in net income declining 47.9% to $17.6M from $33.7M. Cash from operating activities improved sharply to $50.9M from $22.3M, though cash and equivalents decreased to $49.7M.

• ·Expenditures for PP&E and mineral interests: $53.3M in 2025 (down $2.1M YoY)
• ·Pension settlement charge: $7.8M in 2025
• ·Closed mine obligations: $24.7M at Dec 31, 2025 (down from $25.8M)
• ·Gain on settlement of excess funding liability: $3.6M in 2025

04-03-2026

OmniAb, Inc. reported total revenue of $18.7M for the year ended December 31, 2025, down 29% YoY from $26.4M, primarily due to sharp declines in license and milestone revenue (-30%) and service revenue (-39%), while xPloration revenue was newly introduced at $0.8M (+100%) and royalty revenue grew 52%. Total costs and operating expenses fell 13% to $87.6M, improving loss before taxes by 7%, but net loss widened 4% to $64.8M amid a reduced tax benefit. Cash used in operating activities improved to $36.5M from $39.7M, supported by $27.9M in financing inflows.

• ·Diluted EPS improved to $(0.57) from $(0.61) YoY.
• ·Total assets declined to $300.9M from $325.6M as of Dec 31.
• ·Accumulated deficit grew to $166.2M from $101.4M.
• ·Stockholders' equity decreased to $267.0M from $287.6M.

04-03-2026

Viemed Healthcare, Inc. reported FY2025 revenue of $270.3M, up 20.5% YoY from $224.3M, with strong growth in equipment sales (+62.7% to $50.3M) and PAP therapy patients (Q4: 34,528 vs. 21,338 prior year). Net income attributable to the company increased 32.6% to $14.9M, and adjusted EBITDA reached $61.4M across quarters. However, gross margin declined to 57.5% from 59.4%, SG&A rose 14.3% to $121.4M, and net cash decreased $4.0M due to higher investing outflows of $50.2M.

• ·Vent patients Q4 2025: 12,259 (up from 11,795 Q4 2024, +3.9%)
• ·Investing cash outflows FY2025: $50.2M (vs. $30.7M FY2024)
• ·R&D expenses FY2025: $3.0M (down 1.7% YoY)

04-03-2026

Orthopediatrics Corp (KIDS) reported net revenue of $236.3M for FY 2025, up 15% YoY from $204.7M, with U.S. revenue at $186.4M (79% of total, +16% YoY) and international at $50.0M (21%, +15% YoY); product categories showed Trauma & Deformity up 15% to $166.3M (70%), Scoliosis up 20% to $66.0M (28%), but Sports medicine/other down 10% to $4.0M (2%). However, net loss widened 5% YoY to $39.6M amid higher sales & marketing (+13%), G&A (+17%), impairment (+153%), and restructuring (+53%) expenses, despite R&D down 18%; operating loss increased to $39.2M. Cash and restricted cash decreased $24.2M to $21.6M, with total assets at $508.6M but stockholders' equity down to $346.6M.

• ·Gross profit $172.7M FY2025 (+16% YoY from $148.6M).
• ·Operating expenses totaled $211.9M (+15% YoY).
• ·Long-term debt increased to $48.2M term loan and $48.5M convertible note.
• ·Accumulated deficit grew to $275.2M.
• ·Shares outstanding increased to 25.1M from 24.2M.

04-03-2026

Riley Exploration Permian, Inc. (REPX) reported net oil and natural gas sales of $392M for the year ended December 31, 2025, down 4% YoY from $410M in 2024, driven by lower realized oil prices ($62.95/Bbl vs. $74.10) despite a 29% increase in total production to 10,660 MBoe (daily volumes up to 29,205 Boe/d from 22,546). Oil production rose 15% to 6,328 MBbls, but natural gas and NGL sales posted net losses of $3.3M and $3.0M respectively due to elevated GP&T costs ($57.8M total). Average operating costs per Boe improved slightly, with LOE at $8.21 vs. $8.66 YoY.

• ·Natural gas sales net loss widened to $(3.3M) in 2025 from $(1.4M) in 2024 due to higher GP&T costs.
• ·NGL sales turned to net loss of $(3.0M) in 2025 from $2.3M profit in 2024.
• ·Production and ad valorem taxes per Boe declined to $2.73 in 2025 from $3.57 in 2024.

04-03-2026

Middleby Corp reported FY2025 net sales of $3.2B, up 1.6% YoY from $3.2B, with Food Processing segment growing 10.4% to $850.2M while Commercial Foodservice declined 1.2% to $2.4B. Net earnings from continuing operations decreased 12.8% to $367.3M (11.5% margin vs 13.4%), but overall net loss was $277.7M due to $645.0M discontinued operations loss from $704.4M impairments in Residential Kitchen Equipment Group. Stockholders' equity fell to $2.8B from $3.6B, impacted by $729.7M treasury stock repurchases.

• ·Cash and cash equivalents declined to $222.2M from $638.8M YoY.
• ·Long-term debt decreased to $2.1B from $2.4B.
• ·Goodwill balance $1.8B as of Jan 3, 2026.
• ·Impairment test performed as of Sep 27, 2025 for Residential Kitchen Equipment Group.
• ·Current assets held for sale - discontinued operations: $1.1B as of Jan 3, 2026.

04-03-2026

Proved reserves grew 14% YoY to 153.3M Boe as of December 31, 2025, driven by purchases of minerals in place (+14M Boe) and extensions/discoveries (+11.2M Boe), with oil up 12%, gas up 18%, and NGL up 19%. However, the standardized measure of discounted future net cash flows declined 9% YoY to $1.12B due to lower prices, including oil sales down 15% to $63.53/Bbl and total per Boe down 18% to $41.55/Boe, while gas prices remained negative at -$1.33/Mcf. Pre-tax PV-10 value stood at $1.32B, with top three customers (Phillips 66, Concord Energy, NGL Crude) comprising 89% of revenues.

• ·Phillips 66 represents 67% of revenues and 66% of accounts receivable.
• ·Texas reserves account for nearly 100% of total proved reserves (152.98M Boe).
• ·No purchases or sales of minerals in place from New Mexico.
• ·Future production costs as of Dec 31, 2025: $2.47B.
• ·Revisions to previous quantity estimates added 1.34M Boe net in 2025.

04-03-2026

SES AI Corp reported revenue of $21M for 2025, surging 929% YoY from $2M in 2024, with gross profit rising 778% to $11.3M. Operating expenses declined 15% to $93.9M, narrowing the operating loss to $82.6M from $109M. However, cash used in operations was $58M (improved from $66M), investing activities showed a $39M outflow versus $108M inflow prior year, resulting in a net cash decrease of $99M compared to a $42M increase in 2024.

• ·Cost of revenue increased 1,189% YoY to $9.7M from $0.8M.
• ·R&D expenses decreased 7.1% YoY to $67M.
• ·G&A expenses decreased 30% YoY to $26.9M.
• ·Financing activities used $2M cash in 2025 vs provided $1M in 2024.
• ·No goodwill impairment as of Dec 31, 2025 following quantitative assessment.

04-03-2026

Seaport Entertainment Group Inc. (SEG) highlights strong performance at The Rooftop at Pier 17 venue, hosting 62 concerts in 2025 (up from 60 in 2024) and selling 190,000 tickets representing 89% of available inventory, with plans to expand meeting space to 41,000 sq ft for up to 1,500 guests. However, the company warns of ongoing significant negative operating cash flow and net losses expected to continue, potential adverse impacts from regulatory changes, Spin-Off tax risks, MLB PDL control over revenues, and constraints from debt service on cash flow.

• ·Rooftop at Pier 17 voted #1 outdoor music venue in NYC in 2022 by Red Bull, ranked 7th top club worldwide by Pollstar in 2025, and awarded Best Outdoor Music Venue by 2026 Rolling Stone Audio Awards.
• ·MLB PDL may control ticket tax, advertising inventory, and merchandise licensing/royalties for Aviators.

04-03-2026

BioLargo, Inc. reported a consolidated net loss of $15.2M for the year ended December 31, 2025, more than tripling from $4.3M in 2024, driven by Clyra Medical's loss widening to $6.6M from $3.5M and ONM Environmental swinging to a $2.2M loss from a $6.0M profit; however, losses narrowed at BLEST (24% less loss), BETI, BEST, BioLargo Canada, and corporate. Selling, general, and administrative expenses increased 26% YoY to $11.8M, reflecting higher salaries (+44%), consulting (+27%), and office expenses. Total assets fell 21% to $8.3M from $10.5M, with stockholders' equity plunging 75% to $1.5M amid $11.8M added to accumulated deficit and common shares diluting to 317M from 301M.

• ·No dividends paid historically or anticipated in the future.
• ·Equity compensation: 58.8M securities under approved plans ($0.20 weighted avg exercise price), 13.8M under non-approved ($0.39), 31.2M warrants ($0.29); 25.2M shares available for future issuance under approved plans.
• ·Accounts receivable declined sharply to $0.6M from $3.2M.
• ·Clyra Medical debt obligations totaled $1.9M (net of discount), up significantly from prior year.

04-03-2026

Latham Group, Inc. reported net sales of $545.9M for the year ended December 31, 2025, up 7.4% YoY from $508.5M in 2024, though still 3.6% below $566.5M in 2023. The company swung to net income of $11.1M (2.0% margin) from a $17.9M loss in 2024, driven by gross margin expansion to 33.4% (+3.2 pp YoY) and Adjusted EBITDA growth to $99.8M (18.3% margin, +2.5 pp), while operating income rose to $30.6M (+67.3% YoY). However, SG&A expenses increased to 22.5% of sales (+1.2 pp YoY), amortization was flat at 5.3%, and 2024 sales had declined 10.2% from 2023.

• ·Basic EPS $0.10 for 2025 vs $(0.15) for 2024.
• ·Net cash from operating activities $63.4M in 2025, up slightly from $61.3M in 2024 but down from $116.4M in 2023.
• ·Cash balance $71.0M as of Dec 31, 2025, up from $56.4M as of Dec 31, 2024.
• ·Total stockholders’ equity $405.9M as of Dec 31, 2025, up from $387.2M as of Dec 31, 2024.
• ·Weighted-average basic shares 116.4M in 2025 vs 115.4M in 2024.

04-03-2026

Roman DBDR Acquisition Corp. II, a SPAC, reported net income of $7.7M for the year ended December 31, 2025, up significantly from $0.2M in the 2024 inception period, driven by $9.7M in interest income as the Trust Account grew 19.8% to $241.2M with 23M Class A shares redeemed at $10.49 per share. However, operating expenses surged nearly 11x to $2.3M, cash declined 85.6% to $0.18M, accounts payable rose to $0.9M, and shareholders' equity flipped to a $0.8M deficit from a $1.2M surplus. The company may receive up to $1.5M in Working Capital Loans convertible to warrants and has a $0.2M promissory note from a related party.

• ·Shareholders’ equity shifted to ($778,093) deficit as of Dec 31, 2025 from $1,195,391 surplus in 2024.
• ·Promissory note - related party of $200,000 outstanding as of Dec 31, 2025.
• ·Audited by firms with PCAOB ID 688 and 199.
• ·Company inception date: July 25, 2024.
• ·Filing date: March 04, 2026.

04-03-2026

Safeguard Acquisition Corp. (SAC-UN), a blank check company with no operating history or revenues since inception on June 27, 2025, reported total assets of $232.3M as of December 31, 2025, driven by $230.5M in cash and investments held in its Trust Account from 23,000,000 Class A Ordinary Shares at $10.02 per share redemption value. However, the company recorded an accumulated deficit of $7.5M and total shareholders’ deficit of $7.5M due to formation and operating costs, with total liabilities of $9.3M including a $9.2M deferred underwriting fee. It continues seeking a business combination target with significant revenue growth potential and long-term contract visibility.

• ·Balance sheet as of December 31, 2025, covering period from inception June 27, 2025.
• ·Prepaid insurance short-term: $67,508; long-term: $62,426.
• ·Audited by Independent Registered Public Accounting Firm (PCAOB ID 206).

04-03-2026

Everspin Technologies Inc. reported FY 2025 total revenue of $55.2M, up 9.5% YoY from $50.4M, driven by product sales growth of 14.4% to $48.3M, while licensing, royalty, and other revenue declined 15.7% to $6.9M. Gross profit rose to $28.2M (51.2% margin, down slightly from 51.8%), and operating loss narrowed to $6.5M from $7.1M, but the company reported a net loss of $0.6M versus a $0.8M profit in 2024. Regionally, APAC revenue surged to $34.5M (up 20.4% YoY), North America was flat at $10.9M, and EMEA fell to $9.8M (down 11.0% YoY).

• ·Total operating expenses increased to $34.8M (63% of revenue) from $33.2M (66% of revenue).
• ·R&D expenses rose 2.9% to $14.1M (26% of revenue, down from 27%).
• ·G&A expenses up 2.9% to $14.6M (26% of revenue, down from 28%).
• ·Sales and marketing up 13.4% to $6.1M (11% of revenue, flat).